Piper Jaffray Reaffirms Their Buy Rating on Eagle Pharmaceuticals

By Jason Carr

In a report released yesterday, David Amsellem from Piper Jaffray reiterated a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), with a price target of $79. The company’s shares closed yesterday at $59.02.

According to TipRanks.com, Amsellem is ranked 0 out of 5 stars with an average return of -2.2% and a 44.2% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Supernus Pharmaceuticals, and Collegium Pharmaceutical.

Eagle Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $62.

Eagle Pharmaceuticals’ market cap is currently $880.6M and has a P/E ratio of 9.52. The company has a book value ratio of 5.1476.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eagle Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the provision of injectable products. Its activities include development and commercialization of pharmaceutical products for the treatment of areas such as critical care, orphan diseases, and oncology. The company was founded by Scott L.